Olema Pharmaceuticals, Inc. (OLMA) Form 10-Q — Aug 10, 2026

$OLMAForm 10-QFiled Aug 10, 2026, 4:10 PM ET0001193125-26-342383Original filing

Olema Pharmaceuticals filed its Q2 2026 10-Q reporting a net loss of $63.2 million, or $0.61 per share, widened from $43.8 million ($0.51) a year earlier, as R&D expense rose 32% to $57.8 million and G&A more than doubled to $9.4 million on late-stage operations. First-half net loss reached $116.3 million versus $74.2 million in the prior-year period. The balance sheet remains well stocked: cash, cash equivalents and marketable securities totaled $461.1 million at June 30, 2026, and management states this plus the available SVB credit facility balance is sufficient to fund the operating plan for at least the next 12 months.

Key figures

Guidance: Cash, equivalents and marketable securities of $461.1M plus available Loan Agreement balance sufficient to fund the current operating plan for at least the next 12 months; OPERA-01 Phase 3 topline expected Q1 2027, NDA submission 2027, potential FDA approval and commercial launch 2028; OP-3136 combination data mid-2027; Bayer NUBEQA combination arm to initiate Q4 2026.
Total Debt: 3000000
Debt Amount: 3000000
Total Assets: 486578000
Cash Position: 461100000
Interest Rate: greater of 6.0% or the prime rate
Maturity Date: January 1, 2029
Shares Outstanding: 87497607
H1 2026 stock comp: 23051000
Nov 2025 follow on: 11,500,000 shares at $19.00; net proceeds $204.8 million
Q2 2026 ga expense: 9394000
Accumulated deficit: 713846000
Q2 2026 rnd expense: 57785000
Cash and equivalents: 48599000
Marketable securities: 412471000
Atm net proceeds h1 2026: 41.9 million (1,712,739 shares at weighted-average $24.92)
Prefunded warrant shares: 13594149
Novartis repayment amount: proportion of approximately $275 million payable upon a change of control or palazestrant compound transaction with a third party
Q2 2026 ga expense yoy pct: 137
H1 2026 operating cash used: 91883000
Q2 2026 rnd expense yoy pct: 32
2024 private placement gross: $250.0 million (net ~$237.0 million)
Svb credit facility capacity: $100.0 million

Price after filing

1 day: 0.0%7 days: -10.6%30 days: -8.8%

Close on the filing date to close N calendar days later (from $12.05). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.